<DOC>
	<DOCNO>NCT02916056</DOCNO>
	<brief_summary>This open-label extension study patient mild Alzheimer 's disease complete participation azeliragon Phase 3 ( STEADFAST ) trial . Patients receive azeliragon 5 mg/day 2 year .</brief_summary>
	<brief_title>2-Year Extension Study Azeliragon Subjects With Alzheimer 's Disease ( STEADFAST Extension )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion Study TTP488301 Month 18 Visit without ongoing serious adverse event history serious adverse drug reaction study TTP488301 . Patients must enroll present study within 7 day completion study TTP488301 . Evidence personally sign date informed consent document indicate subject ( legally authorize representative ) caregiver/informant inform pertinent aspect study . Participants must able provide assent ( accordance local law , regulation ethic committee policy ) assent may reevaluate study regular interval . Participants caregiver/informants willing able comply schedule visit , treatment plan , laboratory test , study procedure . The subject must reliable caregiver/informant regular contact ( i.e. , 10 hour week combination facetoface visit telephone contact acceptable ) facilitate subject 's full participation study . Caregivers/informant must sufficient subject interaction able provide meaningful input rating scale administer study caregiver/informant input require , particular CDR evidence document source documentation . Participants reside assist living facility permit provided meet caregiver/informant criterion . Participants caregiver/informants must able read , write , speak language psychometric test provide visual auditory acuity ( correct ) sufficient allow accurate psychometric testing . Subject must able ingest oral medication . The subject felt investigator unsuitable ( basis health , compliance , caregiver availability , reason ) inclusion study . Subjects serious suicide risk . If `` yes '' answer item 4 , 5 behavioral question CSSRS , suicide risk assessment must do qualified mental health professional expertise evaluation suicidality elderly ( e.g. , psychiatrist , geriatrician neurologist specialize treatment patient AD ) determine whether safe subject participate study . Subjects demonstrate QTcF &gt; 480 msec &gt; 45 msec change TTP488301 Baseline value base locally read ECG perform TTP488301 Month 18 Visit ( TTP488303 Baseline ) . Participants known history bundle branch block ( either right leave ) allow absolute QTcF value exceed 500 msec . Participants function pacemaker , indicate ECG display paced rhythm , allow QTc upper limit . Other acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may prevent subject complete 2year study may interfere interpretation study result , judgment investigator , would make subject inappropriate entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>RAGE</keyword>
	<keyword>ADAS-cog</keyword>
	<keyword>CDR-sb</keyword>
</DOC>